Business Context and Reporting Period
This Form 8-K filing by Nabors Industries Ltd. (NBR) is dated May 5, 2020. The primary purpose of the report is to disclose the entry into a Material Definitive Agreement involving a Shareholder Rights Plan (Poison Pill) and to reference the announcement of financial results for the quarter ended March 31, 2020.
Key Financial Metrics and Capital Structure
The filing references the Q1 2020 earnings release but does not contain specific numerical values for revenue, profit, cash flow, or margins within the text of this 8-K. Specific capital structure data provided includes:
- Outstanding Common Shares: 8,390,091 as of April 30, 2020.
- Preferred Shares Reserved: 32,000 Series B Junior Participating Preferred Shares reserved for issuance upon exercise of Rights.
- Right Exercise Price: $58.08 per one one-thousandth of a Preferred Share.
- Redemption Price: $0.01 per Right.
Material Changes and Corporate Actions
The most significant material change reported is the adoption of a Shareholder Rights Agreement on May 5, 2020. Key terms include:
- Trigger Threshold: The plan is triggered if any person or group acquires beneficial ownership of 4.9% or more of the Common Shares.
- Grandfathering: Existing shareholders at or above the 4.9% threshold at the time of announcement are grandfathered but become "Acquiring Persons" if they increase ownership by 0.5% or more.
- Expiration: Rights expire on April 30, 2021, unless extended or redeemed.
- Redemption: The Board may redeem the Rights in whole at $0.01 per Right at any time prior to an Acquiring Person emerging.
- Flip-In/Flip-Over: Upon a triggering event, holders (excluding the Acquiring Person) may exercise Rights to purchase securities with a market value of two times the exercise price.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, revenue forecasts, or management commentary on operational outlook within the text. It notes that a conference call regarding Q1 2020 results was scheduled for May 6, 2020. The primary risk disclosed is the potential dilution of existing shareholders in the event of an unsolicited takeover attempt, which the Rights Plan is designed to mitigate. The filing also notes that the Rights Agreement can be amended by the Board without shareholder consent, provided no Acquiring Person exists.
Investor Verification Checklist
- Verify the specific Q1 2020 financial results (revenue, net income, cash flow) in the referenced Press Release (Exhibit 99.1) as they are not detailed in this 8-K.
- Confirm the current trading price of NBR common shares relative to the $58.08 exercise price of the Rights.
- Review the full Rights Agreement (Exhibit 4.1) for specific definitions of "Acquiring Person" and "Associate."
- Monitor for any Board announcements regarding the redemption of Rights or amendments to the plan.
- Check for any subsequent filings regarding the 32,000 Series B Preferred Shares if the Rights are exercised.